In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hair Dye Safety in Europe

This article was originally published in The Rose Sheet

Executive Summary

The Scientific Committee on Consumer Products publishes a memo March 29 notifying the European Commission of its finding that hair-dye ingredients have the potential to cause skin sensitization and allergic reactions. The memo provides "an authoritative overview of the current situation on the degree of sensitization potential of the assessed hair dye substances" and "indicates to the industry and to the research community that hair dyes need further innovative development in order to minimize potential adverse health effects to consumers," according to SCCP, which adopted the opinion during its 10th plenary meeting on Dec. 19, 2006. Though this is not the first time hair dyes have been subjected to SCCP's scrutiny, the committee's opinions to date have largely concerned the general toxicology of the substances...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel